晚期尿路上皮癌-话题@MedSci

#晚期尿路上皮癌#

30篇内容 | 2177人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1440246, encodeId=58e114402464b, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, objectType=article, longId=185039, objectId=2317185039ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2317185039ae, replyNumber=0, likeNumber=67, createdTime=2019-12-23, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2317185039ae, moduleTitle=Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2317185039ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440245, encodeId=437d144024558, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, objectType=article, longId=183278, objectId=22bb1832e804, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22bb1832e804, replyNumber=0, likeNumber=87, createdTime=2019-11-21, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22bb1832e804, moduleTitle=Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22bb1832e804)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440244, encodeId=fca61440244f2, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=J Clin Oncol:免疫药物治疗伴有害DDR突变晚期尿路上皮癌有效率达80%, objectType=article, longId=131677, objectId=aa771316e76f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa771316e76f, replyNumber=0, likeNumber=52, createdTime=2018-03-08, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa771316e76f, moduleTitle=J Clin Oncol:免疫药物治疗伴有害DDR突变晚期尿路上皮癌有效率达80%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa771316e76f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440243, encodeId=0bd21440243fc, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, objectType=article, longId=131112, objectId=8a26131112d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a26131112d7, replyNumber=0, likeNumber=95, createdTime=2018-03-03, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a26131112d7, moduleTitle=JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a26131112d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440242, encodeId=f86914402422a, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=JAMA Oncology:晚期尿路上皮癌患者的曙光！, objectType=article, longId=130648, objectId=bfd8130648b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfd8130648b0, replyNumber=0, likeNumber=80, createdTime=2018-02-27, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfd8130648b0, moduleTitle=JAMA Oncology:晚期尿路上皮癌患者的曙光！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfd8130648b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440241, encodeId=e9cb1440241b9, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=PDL-1和CTLA-4招募晚期尿路上皮癌患者, objectType=article, longId=102247, objectId=8ed610224e25, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ed610224e25, replyNumber=0, likeNumber=74, createdTime=2017-06-18, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ed610224e25, moduleTitle=PDL-1和CTLA-4招募晚期尿路上皮癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ed610224e25)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440240, encodeId=224214402404e, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Lancet Oncology：长春氟宁用于晚期尿路上皮癌的维持治疗, objectType=article, longId=94694, objectId=413094694c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=413094694c0, replyNumber=0, likeNumber=50, createdTime=2017-04-06, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=413094694c0, moduleTitle=Lancet Oncology：长春氟宁用于晚期尿路上皮癌的维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=413094694c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440239, encodeId=fddc1440239c0, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, objectType=article, longId=89310, objectId=b04a893104a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b04a893104a, replyNumber=0, likeNumber=74, createdTime=2017-02-20, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b04a893104a, moduleTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b04a893104a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440238, encodeId=8a3c144023815, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, objectType=article, longId=88389, objectId=549e88389de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=549e88389de, replyNumber=0, likeNumber=56, createdTime=2017-02-08, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=549e88389de, moduleTitle=重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=549e88389de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440237, encodeId=fc02144023eed, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Lancet：Atezolizumab可作为晚期尿路上皮癌顺铂的替代治疗, objectType=article, longId=83782, objectId=f08b83e82fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f08b83e82fc, replyNumber=0, likeNumber=70, createdTime=2016-12-09, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f08b83e82fc, moduleTitle=Lancet：Atezolizumab可作为晚期尿路上皮癌顺铂的替代治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f08b83e82fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440236, encodeId=3de7144023654, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素, objectType=article, longId=61453, objectId=921a6145366, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=921a6145366, replyNumber=0, likeNumber=69, createdTime=2016-01-01, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=921a6145366, moduleTitle=BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=921a6145366)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440235, encodeId=6d2d1440235b1, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响, objectType=article, longId=48845, objectId=b0c248845ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0c248845ee, replyNumber=0, likeNumber=59, createdTime=2015-04-02, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0c248845ee, moduleTitle=Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0c248845ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1440234, encodeId=908714402348c, content=<a href='/topic/show?id=89795982594' target=_blank style='color:#2F92EE;'>#晚期尿路上皮癌#</a>, objectTitle=晚期尿路上皮癌的二线治疗探索, objectType=article, longId=47674, objectId=62064e67496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62064e67496, replyNumber=0, likeNumber=76, createdTime=2015-03-05, rootId=0, userName=1249894fm74暂无昵称, userId=36294710956, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62064e67496, moduleTitle=晚期尿路上皮癌的二线治疗探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62064e67496)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

晚期尿路上皮癌

2020-05-29

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Seattle Genetics/Astellas的抗体-药物偶联物Padcev治疗晚期尿路上皮癌，获得FDA批准

2019-12-23

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Lancet Oncol：Ramucirumab联合多西他奇用于铂难治性晚期尿路上皮癌

2019-11-21

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

J Clin Oncol:免疫药物治疗伴有害DDR突变晚期尿路上皮癌有效率达80%

2018-03-08

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

JCO：DNA损伤反应和修复基因改变作为晚期尿路上皮癌PD-1/PD-L1阻断获益的标志物

2018-03-03

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

JAMA Oncology:晚期尿路上皮癌患者的曙光！

2018-02-27

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

PDL-1和CTLA-4招募晚期尿路上皮癌患者

2017-06-18

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Lancet Oncology：长春氟宁用于晚期尿路上皮癌的维持治疗

2017-04-06

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？

2017-02-20

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

重磅！美国FDA批准百时美PD-1免疫疗法Opdivo治疗晚期尿路上皮癌（mUC）（CheckMate-275）

2017-02-08

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Lancet：Atezolizumab可作为晚期尿路上皮癌顺铂的替代治疗

2016-12-09

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

BMC Cancer：GP方案无效的晚期尿路上皮癌患者MVAC化疗效果预测因素

2016-01-01

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

Clin Genitourin Cancer：先前治疗的等级和围手术期化疗对晚期尿路上皮癌患者的影响

2015-04-02

1249894fm74暂无昵称 (审核中...)

前往app查看评论内容

#晚期尿路上皮癌#

晚期尿路上皮癌的二线治疗探索

2015-03-05

科室
- - 订阅+
  - 更多科室
工具
服务